Dear Editor, Keloid is an irreversible, progressive hypertrophic dermal disorder characterized by continuous and histologically localized inflammation. Destructive nature of keloids leads to significant cosmetic impacts on the healthcare systems, especially on the exposed area, which implies the necessity of its proper management. It has been demonstrated that patients' quality of life has a significant negative correlation with the severity and number of keloids. There is still a significant lack of guidelines regarding the management of keloid, especially recalcitrant lesions. Among currently use strategies, very few medicines have shown to be effective in complete improvement of recalcitrant keloid lesions. Intralesional corticosteroids are the most widely accepted agents in this regard. Unfavorable side effects of these agents, especially in multiple injections with a short interval and high dose in each session, have led to many kinds of research trying to find novel strategies for keloid based on its underlying pathophysiological defects. [1, 2] Currently, many clinical trials are looking at new treatments for keloid, and many of them are actively recruiting. Some of these studies are based on decreasing the collagen synthesis by the immune system and change the level of cytokines, but others reflect a broadening range of possible treatment approaches based on other theories about keloid. Previous immunohistochemical studies showed the role of some growth factors in keloids pathophysiology. [3] Among them, vascular endothelial growth factor (VEGF) has a unique role. Keloids are angiogenic lesions, and superimposed epidermis is the leading cause of keloid angiogenesis. Le et al. have suggested that VEGF is involved in two different pathophysiologic processes necessary for the development of keloids: first, durable inflammation or fibroplasia, and second, an imbalance in extracellular matrix metabolism. [4] The importance of VEGF in the development and exaggerated of hypertrophic scar and keloid had led to trials of medications with antivascular and antiangiogenesis properties. [5] Previous in vitro studies also suggested that corticosteroids can suppress the synthesis of VEGF. [6] Hence, modulation of VEGF production could comprise an appreciated treatment modality for keloids. Bevacizumab (Avastin ® ) and aflibercept (EYLEA ® ) are two examples of medicines with anti-VEGF activity. Bevacizumab, a recombinant
Donor's Versus Recipient's Demographic Data for Estimating Kidney Function in Kidney Transplant Recipients
Dear Editor, Estimated glomerular filtration rate (eGFR) is clinically used to evaluate the level of kidney function and approximating maintenance doses of drugs that are renally eliminated.
Most commonly used equations for eGFR calculation are the chronic kidney disease epidemiology collaboration, modification of diet in renal diseases, and Cockcroft-Gault. These three formulas use serum creatinine concentration to estimate GFR. [1] All these equations, although with different accuracies, can be applied to estimate drug dosing. [1] In kidney transplant recipients, allograft rejection and drug-induced nephrotoxicity are the two persistent threats that necessitate kidney function monitoring. Some investigators have assessed the accuracy of commonly used eGFR equations in kidney transplant recipients. One can conclude that they have used recipients' age, weight, and gender in these eGFR formulas since there is no mention of the donors' data in those studies. [2, 3] They noted that predictive performances of many eGFR equations are modest in kidney transplant recipients, while biases may significantly be associated with recipients' demographic characteristics including body mass index, age, and sex. [2, 3] These discrepancies may in part be due to the using of recipients' biometric data without considering donor's demographic data for estimating GFR. Patients' demographic characteristics including age, sex, race, and weight are usually considered in eGFR equations since they represent interindividual variations in muscle mass and creatinine production. [2, 3] Age is a physiologic factor that affects GFR as well as creatinine production and tubular secretion. [4] In addition, pathologic conditions that are common in older patients (such as diabetes and atherosclerosis) as well as physiologic senescence may alter the accuracy of GFR estimates. [4] Although not clearly mentioned in the method sections of most studies, one can conclude that all of those studies included demographic characteristics of the kidney transplant recipients in the eGFR equations. Considering the role of age on serum creatinine production may justify the use of recipient's age in equations; however, considering the age of the kidney, donor's age may also need to be taken into account. It seems that evaluating eGFR of paired kidneys from a single donor in two different recipients at different time points after transplantation would be worthy in future studies to assess the role of donors' demographic data on eGFR.
Multiple other factors influence the serum creatinine concentration in kidney transplant recipients. For example, trimethoprim that is administered as a component of cotrimoxazole ® for prophylaxis of Pneumocystis jiroveci pneumonia inhibits tubular secretion of creatinine. Corticosteroids that are usually administered as induction and maintenance immunosuppressive regimen induce muscle wasting and affect creatinine generation. [5] Hence, higher doses of steroids within the 1 st day after transplantation and lower doses later may alter serum creatinine concentrations. Therefore, developing new eGFR equations for use in kidney transplant recipients by including demographic data of the donor, drugs types, and steroid dose may be necessary to optimize the accuracy of eGFR in this population.
